Cite
HARVARD Citation
Spinner, C. et al. (2022). Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254 . Clinical infectious diseases. pp. 786-794. [Online].